Delayed Nyse  -  04:03 2022-08-10 pm EDT
89.19 USD   -0.37%
07:16aStarpharma, Merck & Co. Ink New Drug Delivery Research Deal
08/09Merck's Diabetes Drug Januvia Found to Contain Potential Carcinogen; Shares Briefly Slide Into Negative Territory
08/09Cerevance Multi-Year Strategic Research Collaboration with Merck
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca and Merck - LYNPARZA (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

06/28/2022 | 10:22am EDT

RAHWAY, N.J. - AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of LYNPARZA for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.

The CHMP based its positive opinion on results from the Phase 3 OlympiA trial presented during the 2021 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine in June 2021.

Breast cancer is the most commonly diagnosed cancer worldwide, with an estimated 2.3 million patients diagnosed in 2020. In the European Union (EU), one in seven people who were assigned female at birth will develop breast cancer in their lifetime. Approximately 75% of breast cancer patients worldwide are diagnosed with early breast cancer; however, a quarter of these patients will experience disease recurrence following surgery. In Europe, germline BRCA mutations are found in approximately 9% of patients.

Professor Andrew Tutt, Global Chair of the OlympiA Phase III trial and Professor of Oncology at The Institute of Cancer Research, London and King's College London, said: 'For patients with high-risk, early-stage breast cancer, the risk of recurrence remains unacceptably high, and cancer will return for more than one in four of these patients. Today's recommendation is hopeful news for patients in Europe, as we move closer to setting a potential new standard of care that improves overall survival in patients suitable for treatment with olaparib.'

Susan Galbraith, executive vice president, oncology R&D, AstraZeneca, said, 'If approved, LYNPARZAwill provide a new targeted treatment option for patients with germline BRCA-mutated, HER2-negative early breast cancer in Europe. By treating patients as early as possible in their disease, we hope to avoid life-threatening recurrence and give people more time with their loved ones.'

Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, said, 'Patients with germline BRCA-mutated, HER2-negative early breast cancer will often develop breast cancer at an earlier age than those without BRCA mutations, impacting people in their prime. Today's positive opinion brings us closer to our goal of offering a much-needed new treatment option to these patients in Europe.'

In the trial, LYNPARZA demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of invasive disease-free survival (IDFS), reducing the risk of invasive breast cancer recurrences, second cancers or death by 42% (HR=0.58 [99.5% CI, 0.41-0.82]; p

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.22% 10818 Delayed Quote.24.66%
MERCK & CO., INC. -0.37% 89.19 Delayed Quote.16.38%
All news about MERCK & CO., INC.
07:16aStarpharma, Merck & Co. Ink New Drug Delivery Research Deal
08/09Merck's Diabetes Drug Januvia Found to Contain Potential Carcinogen; Shares Briefly Sli..
08/09Cerevance Multi-Year Strategic Research Collaboration with Merck
08/08Merck & Co. Continues To Cooperate With US Senate's Tax Probe
08/05Merck - LYNPARZA (olaparib) Approved in the EU as Adjuvant Treatment for Patients With ..
08/05MERCK & CO., INC. Management's Discussion and Analysis of Financial Condition and Resu..
08/04GLOBAL MARKETS LIVE : Bayer, Merck, eBay, MetLife, Eli Lilly...
08/04Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA (pembrolizumab) ..
08/04Merck and eisai provide update on phase 3 leap-002 trial evaluating keytruda (pembroliz..
08/04AstraZeneca Says Lynparza Approved in EU as Adjuvant Treatment for Breast Cancer
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 58 555 M - -
Net income 2022 15 183 M - -
Net Debt 2022 17 391 M - -
P/E ratio 2022 14,7x
Yield 2022 3,13%
Capitalization 226 B 226 B -
EV / Sales 2022 4,16x
EV / Sales 2023 4,12x
Nbr of Employees 67 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 89,19 $
Average target price 100,14 $
Spread / Average Target 12,3%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.16.38%226 779
JOHNSON & JOHNSON-0.23%447 434
PFIZER, INC.-15.70%279 310
ROCHE HOLDING AG-16.02%275 991
ABBVIE INC.3.58%247 976